ES2748590T3 - Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis - Google Patents
Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis Download PDFInfo
- Publication number
- ES2748590T3 ES2748590T3 ES12806846T ES12806846T ES2748590T3 ES 2748590 T3 ES2748590 T3 ES 2748590T3 ES 12806846 T ES12806846 T ES 12806846T ES 12806846 T ES12806846 T ES 12806846T ES 2748590 T3 ES2748590 T3 ES 2748590T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- cancer
- group
- salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*[n](c(*)c1*)c(N=CN2*)c1C2=N Chemical compound C*[n](c(*)c1*)c(N=CN2*)c1C2=N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576780P | 2011-12-16 | 2011-12-16 | |
| PCT/US2012/070155 WO2013090912A1 (en) | 2011-12-16 | 2012-12-17 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2748590T3 true ES2748590T3 (es) | 2020-03-17 |
Family
ID=47436279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12806846T Active ES2748590T3 (es) | 2011-12-16 | 2012-12-17 | Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9663521B2 (OSRAM) |
| EP (1) | EP2791142B1 (OSRAM) |
| JP (2) | JP6463130B2 (OSRAM) |
| AU (2) | AU2012353651B2 (OSRAM) |
| CA (1) | CA2859370C (OSRAM) |
| ES (1) | ES2748590T3 (OSRAM) |
| WO (1) | WO2013090912A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013090912A1 (en) * | 2011-12-16 | 2013-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
| KR102523430B1 (ko) | 2014-08-04 | 2023-04-19 | 누에볼루션 에이/에스 | 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체 |
| US9877966B1 (en) * | 2015-08-10 | 2018-01-30 | Eugene J. Oliva | Combination therapy for the inhibition of metastasis and tumorigenesis |
| WO2018140630A1 (en) * | 2017-01-25 | 2018-08-02 | Northwestern University | Autophagy inducers for treatment of cns conditions |
| JP7421499B2 (ja) * | 2018-05-15 | 2024-01-24 | アメリカ合衆国 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| UY38994A (es) | 2019-12-20 | 2021-07-30 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2024026064A1 (en) * | 2022-07-29 | 2024-02-01 | The University Of North Carolina At Chapel Hill | Enhancing antimetastasis activity using targeted protein degradation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| EP1463742A4 (en) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES |
| EP2190466A4 (en) * | 2007-08-10 | 2011-12-21 | Burnham Inst Medical Research | Tissue-specific alkaline phosphatase (TNAP) activators and their use |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011046646A2 (en) | 2009-07-10 | 2011-04-21 | Microbiotix, Inc. | Inhibitors of filovirus entry into host cells |
| WO2013090912A1 (en) * | 2011-12-16 | 2013-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
| JP6681070B2 (ja) * | 2015-11-19 | 2020-04-15 | 国立大学法人 岡山大学 | 光ファイバ装置及びセンサシステム |
-
2012
- 2012-12-17 WO PCT/US2012/070155 patent/WO2013090912A1/en not_active Ceased
- 2012-12-17 AU AU2012353651A patent/AU2012353651B2/en active Active
- 2012-12-17 JP JP2014547550A patent/JP6463130B2/ja active Active
- 2012-12-17 CA CA2859370A patent/CA2859370C/en active Active
- 2012-12-17 EP EP12806846.7A patent/EP2791142B1/en active Active
- 2012-12-17 ES ES12806846T patent/ES2748590T3/es active Active
- 2012-12-17 US US14/364,759 patent/US9663521B2/en active Active
-
2017
- 2017-05-23 JP JP2017102107A patent/JP6726640B2/ja active Active
- 2017-05-26 US US15/606,740 patent/US10301314B2/en active Active
- 2017-12-13 AU AU2017276258A patent/AU2017276258B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2859370C (en) | 2021-01-26 |
| AU2012353651A1 (en) | 2014-07-10 |
| AU2012353651B2 (en) | 2017-09-14 |
| EP2791142A1 (en) | 2014-10-22 |
| CA2859370A1 (en) | 2013-06-20 |
| JP6463130B2 (ja) | 2019-01-30 |
| AU2017276258B2 (en) | 2019-10-03 |
| JP2017200921A (ja) | 2017-11-09 |
| US10301314B2 (en) | 2019-05-28 |
| US20140323438A1 (en) | 2014-10-30 |
| AU2017276258A1 (en) | 2018-01-18 |
| WO2013090912A1 (en) | 2013-06-20 |
| JP6726640B2 (ja) | 2020-07-22 |
| JP2015502367A (ja) | 2015-01-22 |
| EP2791142B1 (en) | 2019-07-03 |
| US20170260192A1 (en) | 2017-09-14 |
| US9663521B2 (en) | 2017-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2748590T3 (es) | Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis | |
| US12459921B2 (en) | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | |
| ES2620634T3 (es) | Activadores de piruvato quinasa humana | |
| JP6047184B2 (ja) | トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用 | |
| AU2014350729B2 (en) | N-benzyl tryptanthrin derivative, and preparation method and application thereof | |
| ES2906785T3 (es) | Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones | |
| ES2942308T3 (es) | Compuestos y su uso como inhibidores de BACE1 | |
| EP2938610A2 (en) | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof | |
| AU2016272057A1 (en) | Use of pteridinone derivative serving as EGFR inhibitor | |
| CN101171257B (zh) | 吡咯并苯并二氮杂类化合物 | |
| ES2820553T3 (es) | Compuesto y composición farmacéutica para trastorno neuropsicológico o tumor maligno | |
| CN103204822A (zh) | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 | |
| ES2751642T3 (es) | Compuestos inhibidores de bromodominios y composición farmacéutica que los comprende para prevenir o tratar un cáncer | |
| CA3135755A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| WO2013043192A1 (en) | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders | |
| ES2782357T3 (es) | Inhibidores de IRE 1 alfa | |
| ZA200609055B (en) | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics and anticancer agents | |
| ES2609459T3 (es) | Compuestos heterocíclicos condensados y su uso | |
| US20140206645A1 (en) | Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase | |
| US9877966B1 (en) | Combination therapy for the inhibition of metastasis and tumorigenesis | |
| JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
| CN107382967B (zh) | 咔唑磺酰胺衍生物或其可药用盐及其制备方法和应用 | |
| ES2994690T3 (en) | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 | |
| RU2813232C2 (ru) | Соединение изоиндолин, способ получения, фармацевтическая композиция и их применение | |
| EP4671245A1 (en) | HETEROAROMATIC CYCLIC COMPOUND SERVING AS A CDK7 KINASE INHIBITOR, ITS PREPARATION AND USE |